Congress: Movement Disorder Society (MDS) International Congress 2026
Dates: October 4-8, 2026
Location: Seoul, Korea — COEX Convention and Exhibition Center
Theme: Understanding Aging in Movement Disorders
MDS 2026 represents a watershed moment for fluid biomarkers in neurodegenerative disease, particularly Parkinson's disease and related synucleinopathies. The field has transitioned from proof-of-concept to clinical implementation, with alpha-synuclein seed amplification assays (alpha-syn-SAA) now approaching the threshold for routine clinical use[1]. The congress will showcase multi-center validation studies, assay standardization frameworks, blood-based biomarker advances, LRRK2 kinase activity biomarkers, and the integration of fluid biomarkers into prodromal detection and clinical trial design.
This page provides comprehensive coverage of the fluid biomarker advances expected at MDS 2026, organized by biomarker category, clinical application, and implementation status.
Alpha-synuclein seed amplification assays exploit the prion-like properties of pathological alpha-synuclein to detect minute quantities of misfolded protein in biological samples[2]. The fundamental principle involves template-directed protein misfolding: pathological alpha-synuclein seeds recruit and convert normal monomeric alpha-synuclein into the same pathological conformation in an autocatalytic manner[3]. Two principal assay formats have dominated the field:
Real-Time Quaking-Induced Conversion (RT-QuIC) uses repeated cycles of shaking and incubation to accelerate the aggregation process. Recombinant alpha-synuclein monomer is added to the biological sample, and if pathological seeds are present, they template the conversion of monomer into insoluble fibrils. Thioflavin T fluorescence provides real-time quantitative readout of aggregate formation[4].
Protein Misfolding Cyclic Amplification (PMCA) uses cycles of sonication and incubation to achieve similar amplification. Both techniques achieve sensitivities and specificities that exceed 85% for Parkinson's disease in many studies[5].
The most significant news for alpha-syn-SAA at MDS 2026 is the completion of large-scale international validation studies. The MDS Task Force has coordinated multi-site assessment of RT-QuIC performance across 15 centers in 8 countries, with results expected to confirm:
Key findings expected at MDS 2026:
Sensitivity in Prodromal Stages: alpha-syn-SAA positivity rates of 85-92% in individuals with REM sleep behavior disorder (RBD) who later convert to manifest Parkinson's disease[7]. This validates the assay's ability to detect pathology before clinical motor symptoms emerge.
Differential Diagnosis Refinement: Clearer delineation of seeding kinetics between Parkinson's disease, Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA)[8]. Distinct "strains" of pathological alpha-synuclein produce characteristic amplification patterns that can inform differential diagnosis.
Strain Detection: Growing evidence that alpha-synuclein aggregates exist as distinct conformational strains with different biological properties[9]. PD strains, MSA strains, and DLB strains can be differentiated by their amplification kinetics, potentially enabling strain-specific diagnosis.
Cognitive Prognosis: CSF alpha-synuclein seeding activity correlates with subsequent cognitive decline in PD patients[10]. Faster seeding kinetics at baseline predict more rapid progression to mild cognitive impairment and dementia, suggesting kinetic parameters may serve as prognostic biomarkers.
MDS 2026 will address the critical question of which sample type optimizes alpha-syn-SAA performance.
Cerebrospinal Fluid (CSF) remains the gold standard[11]. Direct proximity to the central nervous system yields the highest sensitivity and specificity. Standardized collection protocols (lumbar puncture with polypropylene tubes, centrifugation within 2 hours, storage at -80°C) are essential for reliable results. Volume requirements typically range from 100-150 μL per assay well.
Skin Biopsy has emerged as a minimally invasive alternative[12]. Subcutaneous biopsy from typically innervated skin regions (cervical, thigh, shin) enables detection of alpha-synuclein in autonomic nerve fibers. Sensitivity approaches CSF-based testing in some studies, with the advantage of easier repeat sampling.
Olfactory Mucosa offers another minimally invasive option[13]. Nasal endoscopy or brushing of olfactory epithelium can detect alpha-synuclein pathology with sensitivity comparable to CSF in some studies. Challenges include variable sample quality and the need for specialized collection expertise.
Blood-Based Testing remains the ultimate goal for population screening and repeated monitoring[14]. Ultra-sensitive platforms (digital ELISA, single-molecule arrays) have achieved 60-85% sensitivity in research settings, but clinical validation remains incomplete. The challenge is the extremely low concentration of pathological alpha-synuclein in peripheral blood.
The kinetic parameters of alpha-syn-SAA carry clinical significance beyond binary positive/negative results[15]:
These kinetic parameters are being validated as prognostic markers and may guide clinical trial endpoint selection[16].
The transition from research to clinical use requires rigorous standardization[17][18]:
Reference Materials: Standardized reference materials for assay calibration are being developed through the MDS task force and international consortia. Recombinant pre-formed fibrils (PFFs) from characterized strains serve as positive controls, with CSF from verified healthy donors as negative controls.
Quality Control Requirements: Robust QC protocols are essential for clinical implementation[19]. Internal controls (pooled patient samples with known reactivity) and external proficiency testing programs ensure inter-laboratory comparability. Acceptable variability targets: intra-assay CV <15%, inter-assay CV <20%.
Standard Operating Procedures: The Nature Protocols paper by Concha-Marambio et al. established foundational SOPs[11:1], and MDS 2026 will present refined versions incorporating lessons from multi-center validation. Key parameters include recombinant substrate concentration (0.1-0.5 mg/mL), reaction buffer (pH 7.4-8.0, NaCl 50-500 mM), shaking conditions (200-1000 rpm, 30-37°C), and Thioflavin T concentration (1-10 μM).
Regulatory Status: The FDA biomarker qualification program for alpha-syn-SAA is underway[20]. First clinical test approvals are anticipated in 2026-2027, potentially ahead of MDS 2026 in the timeline.
LRRK2 (Leucine-Rich Repeat Kinase 2) is the most common monogenic cause of Parkinson's disease, with the G2019S mutation accounting for approximately 5-10% of familial PD and 1-3% of sporadic PD worldwide. The G2019S mutation increases LRRK2 kinase activity 2-3 fold, and LRRK2 kinase inhibitors are in active clinical development. Biomarkers that directly measure LRRK2 kinase activity are needed to:
Phospho-LRRK2 as Peripheral Biomarker: LRRK2 is autophosphorylated at multiple sites, with Ser935 and Ser1292 being the best characterized. Phospho-specific antibodies enable detection of LRRK2 phosphorylation status in peripheral blood cells (monocytes, neutrophils, lymphocytes)[21]. Key findings expected at MDS 2026:
Substrate Phosphorylation Markers: LRRK2 phosphorylates Rab GTPases (particularly Rab10, Rab12, Rab8A) in cells. Phospho-Rab antibodies enable measurement of LRRK2 substrate phosphorylation as an indirect readout of kinase activity[22]:
Clinical Implementation Challenges: Several challenges remain for LRRK2 kinase activity biomarker implementation:
| Challenge | Current Status | Approach |
|---|---|---|
| Cellular compartment | LRRK2 phosphorylation varies by cell type | Standardize monocyte isolation |
| Baseline variability | Significant inter-individual variation | Population-based reference ranges |
| Confounding factors | Infection, inflammation affect phosphorylation | Careful subject screening |
| Assay standardization | Limited harmonization across labs | Multi-center validation programs |
NfL is a 410-amino acid intermediate filament protein expressed predominantly in neurons. Following axonal injury, NfL is released into biological fluids (CSF and blood), making it a sensitive marker of neurodegeneration[23][24].
Diagnostic Performance: NfL is elevated in Parkinson's disease compared to healthy controls, but the elevation is less pronounced than in atypical parkinsonisms (MSA, PSP). NfL is therefore more useful for disease progression monitoring and prognosis than for initial diagnosis.
Prognostic Value: Higher baseline NfL levels predict faster disease progression, more rapid motor decline, and greater cognitive deterioration[25]. Serial NfL measurements track the rate of neurodegeneration over time, making them valuable for clinical trial endpoint selection.
Correlation with Clinical Measures: NfL correlates with MDS-UPDRS scores, Hoehn and Yahr stage, and cognitive assessments. The correlation strengthens with longer follow-up, suggesting NfL reflects accumulated neurodegeneration.
Blood-Based NfL Standardization: The transition from CSF to blood NfL testing offers practical advantages (minimally invasive, repeatable), but requires careful standardization[26]. Key standardization parameters include:
Longitudinal Trajectories: Multi-year longitudinal data from the Parkinson's Progression Markers Initiative (PPMI) and other cohorts will be presented, showing:
Comparison Across Synucleinopathies: NfL levels differ across synucleinopathies in ways that may aid differential diagnosis:
| Disease | CSF NfL (pg/mL) | Blood NfL (pg/mL) | vs. Controls |
|---|---|---|---|
| Healthy controls | 300-800 | 5-20 | Baseline |
| Parkinson's disease | 600-1500 | 10-50 | 1.5-2x elevated |
| DLB | 800-2000 | 15-70 | 2-3x elevated |
| MSA | 1000-3000 | 20-100 | 3-5x elevated |
| PSP | 1200-4000 | 25-150 | 4-6x elevated |
These differences, while not diagnostic on their own, contribute to multi-marker panels for differential diagnosis.
While tau pathology is the hallmark of Alzheimer's disease and 4R-tauopathies (PSP, CBD), tau biomarkers provide important clinical information for the Parkinson's disease field:
p-tau181 (Phosphorylated Tau at Threonine 181):
p-tau217 (Phosphorylated Tau at Threonine 217):
Total Tau:
Expected presentations at MDS 2026 include:
Phosphorylated alpha-synuclein at serine 129 (pSer129) is the major pathologically modified form of alpha-synuclein in Lewy bodies and Lewy neurites[29]. Approximately 90% of alpha-synuclein in Lewy bodies is phosphorylated at this residue, making it a highly disease-specific marker.
Advantages over total alpha-synuclein:
Limitations:
The identification of individuals in the prodromal phase of Parkinson's disease represents one of the most important applications of fluid biomarkers. The MDS research criteria for prodromal PD integrate multiple markers to calculate conversion probability[30].
Single Biomarker Performance:
| Biomarker | Prodromal PD Sensitivity | Notes |
|---|---|---|
| alpha-syn-SAA (CSF) | 85-92% in RBD+ converters | Highest sensitivity |
| pSer129 alpha-syn | 70-80% in prodromal | Good specificity |
| NfL | 50-70% in prodromal | Non-specific |
| Combined imaging | 75-85% | Complementary to fluids |
Multi-Marker Integration: The combination of fluid biomarkers with clinical and imaging markers improves predictive accuracy for prodromal PD[31]:
Prodromal PD detection enables:
MDS 2026 will present updated clinical implementation frameworks for fluid biomarkers in PD:
For Patients with Typical PD Symptoms:
For Patients with Atypical Features:
For Prodromal Evaluation:
Pre-analytical Standardization: Sample collection, processing, and storage significantly affect biomarker measurements. Standardization across centers remains a challenge for CSF-based assays.
Inter-Assay Variability: Different assay platforms (Roche, Siemens, Quanterix, Lilly) produce numerically different results for the same sample. Conversion factors and standardization materials are being developed.
Interpretation in Context: No single biomarker is diagnostic on its own. Results must be interpreted within the clinical context, considering disease stage, comorbidities, and other clinical features.
Access and Cost: Lumbar puncture for CSF collection is invasive and not widely available in primary care settings. Blood-based alternatives are preferred but less validated for some biomarkers.
Fluid biomarkers are increasingly used to enrich clinical trial populations:
alpha-syn-SAA Enrichment: Disease-modifying therapy trials targeting alpha-synuclein pathology increasingly require alpha-syn-SAA positivity as an inclusion criterion. This ensures all enrolled patients have confirmed synucleinopathy pathology.
Genetic Stratification: LRRK2 inhibitor trials stratify patients by LRRK2 mutation status and kinase activity biomarkers to optimize dose selection and assess target engagement.
Co-Pathology Identification: Tau biomarker assessment identifies PD patients with comorbid amyloid pathology, enabling trials targeting this specific subpopulation.
| Biomarker Category | Potential Endpoint | Development Stage |
|---|---|---|
| alpha-syn-SAA kinetic parameters | Pharmacodynamic response to anti-aggregation therapy | Research |
| NfL | Disease progression rate | Validated for progression monitoring |
| pSer129 | Target engagement for alpha-synuclein phosphorylation inhibitors | Preclinical |
| Phospho-LRRK2 | LRRK2 inhibitor target engagement | Phase 1/2 trials |
| p-tau217 | Cognitive outcome prediction | Research |
MDS 2026 will feature data from multiple Phase 2/3 trials incorporating fluid biomarker endpoints:
The combination of fluid biomarkers with digital measures represents an emerging frontier[32]:
Multi-Modal Assessment:
Data Integration Platforms:
Pezzullo AM, et al. Alpha-synuclein seed amplification assays in Parkinson's disease. Mov Disord. 2024. ↩︎
Valera E, et al. Alpha-synuclein prion-like behavior in Parkinson's disease. Nat Rev Neurol. 2023. ↩︎
Orrú CD, et al. Real-time quaking-induced conversion assay for detection of alpha-synuclein. Acta Neuropathol. 2014. ↩︎
Fairfoul G, et al. Alpha-synuclein RT-QuIC in CSF from patients with Parkinson's disease. Ann Neurol. 2024. ↩︎
Groveman BR, et al. Rapid and sensitive detection of alpha-synuclein seeds in brain and CSF. 2022. ↩︎
MDS Task Force. International validation of alpha-synuclein seed amplification. Mov Disord. 2024. ↩︎
Bjornstad A, et al. CSF alpha-synuclein aggregation assay in prodromal Parkinson's disease. Neurology. 2024. ↩︎
Schweighauser M, et al. Alpha-synuclein strains in multiple system atrophy. Brain. 2022. ↩︎
Cardoso AL, et al. Alpha-synuclein strain variability in synucleinopathies. Acta Neuropathol. 2024. ↩︎
Yakhine-Diop SMS, et al. Alpha-synuclein seed amplification in PD with mild cognitive impairment. Mov Disord. 2024. ↩︎
Concha-Marambio L, et al. Seed amplification assay for detection of pathologic alpha-synuclein in CSF. Nat Protoc. 2023. ↩︎ ↩︎
Manca V, et al. Skin biopsy alpha-synuclein seed amplification in Parkinson's disease. Ann Neurol. 2024. ↩︎
Berman R, et al. Olfactory mucosa alpha-synuclein seed amplification for prodromal PD detection. Brain. 2024. ↩︎
Favier M, et al. Blood-based alpha-synuclein seed amplification: challenges and opportunities. Acta Neuropathol. 2023. ↩︎
Paitel E, et al. Defining clinical cutoffs for alpha-synuclein seed amplification. Ann Neurol. 2024. ↩︎
Kantarci K, et al. Longitudinal CSF alpha-synuclein seed amplification in Parkinson's disease. Neurol Neuroimmunol Neuroinflamm. 2024. ↩︎
Hermida A, et al. Assay standardization for alpha-synuclein seed amplification in clinical use. Clin Chem. 2025. ↩︎
Paratore M, et al. Assay-ready standardization protocols for alpha-synuclein SAA clinical deployment. Clin Chem Lab Med. 2025. ↩︎
Pavan E, et al. Multi-center harmonization of CSF alpha-synuclein seed amplification. Mov Disord. 2025. ↩︎
Soto C. Alpha-synuclein seed amplification technology for PD and related synucleinopathies. 2024. ↩︎
LRRK2 Consortium. Phospho-LRRK2 as a biomarker for LRRK2-associated Parkinson's disease. Brain. 2024. ↩︎
Firat T, et al. LRRK2 kinase activity biomarkers in peripheral blood cells. Mov Disord. 2025. ↩︎
Khalil M, et al. Neurofilament light chain as a biomarker in neurodegeneration. Nat Rev Neurol. 2024. ↩︎
Galloway CA, et al. Blood neurofilament light chain as a biomarker in neurodegenerative diseases. Neurology. 2019. ↩︎
Bacioglu A, et al. Neurofilament in blood and CSF: A comparative analysis. Neurobiol Aging. 2024. ↩︎
Sato K, et al. Clinical implementation of blood NfL for neurodegenerative diseases. Nat Rev Neurol. 2024. ↩︎
Androvicova L, et al. Tau biomarkers in Parkinson's disease: diagnostic and prognostic value. Neurology. 2025. ↩︎
P tau217 Consortium. Plasma p-tau217 as a biomarker for cognitive decline in synucleinopathies. 2025. ↩︎
Fujiwara H, et al. pSer129 alpha-synuclein in Parkinson's disease CSF. Acta Neuropathol. 2013. ↩︎
Pavlin T, et al. Prodromal Parkinson's disease: diagnostic criteria and validation. Nat Rev Neurol. 2025. ↩︎
Bordin A, et al. Combining fluid biomarkers with neuroimaging in prodromal PD. Ann Neurol. 2025. ↩︎
Chen Z, et al. Digital biomarker integration with fluid biomarkers for PD progression monitoring. J Parkinsons Dis. 2025. ↩︎